本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Chemomab Therapeutics Ltd.

1.67
-0.0100-0.60%
盤後1.670.00000.00%19:51 EDT
成交量:5.07萬
成交額:8.46萬
市值:1,202.47萬
市盈率:-1.18
高:1.72
開:1.72
低:1.62
收:1.68
52周最高:5.88
52周最低:1.35
股本:720.04萬
流通股本:637.22萬
量比:1.17
換手率:0.80%
股息:- -
股息率:- -
每股收益(TTM):-1.4103
每股收益(LYR):-1.4400
淨資產收益率:-69.54%
總資產收益率:-38.86%
市淨率:0.97
市盈率(LYR):-1.16

資料載入中...

2026/03/23

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2025/04/04

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/11/29

超過5%披露

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2024/11/21

超過5%披露

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
2024/09/16

超過5%披露

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2024/09/12

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/09/04

SEC問詢函

Form CORRESP - Correspondence
2024/08/20

超過5%披露

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
2024/03/28

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/03/11

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/11/16

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/11/02

SEC問詢函

Form CORRESP - Correspondence
2023/06/16

重要事件披露

Form 8-K - Current report
2023/06/05

重要事件披露

Form 8-K - Current report
2023/05/20

[修訂]招股説明書

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
2023/05/11

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2023/05/11

重要事件披露

8-K - Current report
2023/03/22

[修訂]招股説明書

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
2023/03/21

[修訂]招股説明書

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
2023/03/20

年度報告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]